Aclaris Therapeutics, Inc. - Enterprise Value

The Enterprise Value as of October 2026 (TTM) for Aclaris Therapeutics, Inc. (ACRS) is 465.47M

According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 465.47M. This represents a change of 6.17% compared to the average of 438.40M of the last 4 quarters.

Aclaris Therapeutics, Inc. (ACRS) Historical Enterprise Value (quarterly & annually)

How has ACRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Aclaris Therapeutics, Inc. over the last ten years is 389.41M. The current 465.47M Enterprise Value has changed 11.85% with respect to the historical average. Over the past ten years (40 quarters), ACRS's Enterprise Value was at its highest in in the March 2021 quarter at 1.24B. The Enterprise Value was at its lowest in in the March 2020 quarter at 488.17K.

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aclaris Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aclaris Therapeutics, Inc. (ACRS) Average Enterprise Value

How has ACRS Enterprise Value performed in the past?

The current Enterprise Value of Aclaris Therapeutics, Inc. (ACRS) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value vs. Peers

How is ACRS’s Enterprise Value compared to its peers?

Aclaris Therapeutics, Inc.’s Enterprise Value is less than AnaptysBio, Inc. (1.49B), less than Attovia Therapeutics, Inc. (604.90M), less than Alumis Inc. (782.44M), less than Odyssey Therapeutics, Inc. (770.85M), greater than Immunic, Inc. (-60678865.00), less than First Tracks Biotherapeutics Inc (941.71M), less than MoonLake Immunotherapeutics (499.27M), greater than Aldeyra The (9.33M), greater than AgomAb Therapeutics N.V. American Depositary Shares (166.70M), greater than InflaRx N.V. (58.04M),

Build a custom stock screener for Aclaris Therapeutics, Inc. (ACRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aclaris Therapeutics, Inc. (ACRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.